PharmGen Science, Inc. (KRX:004720)
4,325.00
-40.00 (-0.92%)
Last updated: Jun 23, 2025
PharmGen Science Revenue
PharmGen Science had revenue of 42.88B KRW in the quarter ending March 31, 2025, with 0.87% growth. This brings the company's revenue in the last twelve months to 171.66B, down -0.02% year-over-year. In the year 2024, PharmGen Science had annual revenue of 171.29B with 2.70% growth.
Revenue (ttm)
171.66B
Revenue Growth
-0.02%
P/S Ratio
0.45
Revenue / Employee
759.55M
Employees
226
Market Cap
77.27B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 171.29B | 4.51B | 2.70% |
Dec 31, 2023 | 166.78B | 15.85B | 10.50% |
Dec 31, 2022 | 150.93B | 41.06B | 37.38% |
Dec 31, 2021 | 109.87B | 13.25B | 13.72% |
Dec 31, 2020 | 96.61B | 1.48B | 1.55% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,898.69B |
Celltrion | 3,662.23B |
ALTEOGEN | 151.65B |
Yuhan | 2,114.76B |
SK Biopharmaceuticals | 578.00B |
HLB Co., Ltd. | 74.64B |
PharmaResearch | 392.31B |
Peptron | 4.30B |